Synergy of Humans and Machines in Healthcare

Abstract

This chapter explores the synergy of humans and machines in health care, focusing on how they work together to enhance outcomes in medical practice. By combining human creativity and judgment with the precision and data-processing capabilities of machines, this partnership addresses key shortcomings in contemporary medical practices. It discusses various applications of AI and ML in health care: drug discovery, diagnosis, predictive analysis, telemedicine, and remote patient monitoring. Innovations in technology are revolutionizing the spheres where quicker drug development, enhanced diagnostic accuracy, and cost-cutting are evident. The integration of AI in treatment facilitates personalized medicine through the assessment of vast volumes of data, predicting outcomes, and developing the most optimal treatment plans for each patient. Technologies enhance telemedicine access to healthcare by providing real-time monitoring of chronic disease management and wearable devices equipped with IoT sensors. It will conclude the chapter by stating how this human-machine synergy will revolutionize healthcare delivery and enhance patient care, while also providing innovative solutions in medical research.

INTRODUCTION

The term "synergy" is derived from the Attic Greek word synergia, which is derived from synergos, meaning "working together." The effect of this synergy of humans and machines is that both produce something that can easily turn out to be more than the potential of the single result if one of them works alone; it occurs largely in that people add, creativity and judgment with appropriate context, while computers can better process information and execute actions with high accuracy for innovative and improved productivity in health care and many aspects of manufacturing, scientific investigation, etc.

Technological breakthroughs are revolutionizing nearly every sector, with the health care business poised to gain significantly from these innovations. Significant developments in technology and financing have led to the widespread adoption of machines in healthcare facilities for various activities, including next-generation sequencing, electronic data collection and storage, as well as diagnosis and treatment recommendations. The gathering and analysis of big data have reached extraordinary levels, surpassing human analytical and interpretative capacities, thanks to sensors and innovative algorithms that enable the continuous measurement and storage of patients' health metrics. The conversion of AI technologies and big data into actionable biological and clinical information has expanded, facilitating precision medicine. These algorithms now possess the potential to learn and thus enhance over time. The benefits of employing AI algorithms or neural networks in healthcare are increasingly evident in numerous healthcare systems, resulting in reduced diagnostic errors, resource conservation, and enabling doctors to address the needs of additional patients [1, 2].

The collaboration between humans and AI is becoming a potent tool to rectify the existing deficiencies in medicine.

These deficiencies encompass inadequate prediction accuracy, vulnerability to critical diagnostic and therapeutic mistakes, unexpected repercussions of empirical decision-making, and inefficient hospital procedures, frequently culminating in inferior patient care. AI is poised to transform how urologists provide care for their patients. AI encompasses the scientific, engineering, and developmental processes of systems that replicate human intellect and behaviour. Effective AI encompasses unique insights in perception, pattern recognition for text, audio, and images, as well as decision-making and problem-solving capabilities. Significant progress has been achieved in creating synergistic human-machine systems that leverage the advantages of both human and AI-generated reasoning [3].

The key areas in healthcare include human and machine drug discovery & drug development, diagnosis & predictive analysis, telemedicine and remote patient monitoring, robot-assisted surgery, and hospital management. This book chapter will discuss these topics in detail and how human and machine synergy have impacted them, as well as their future perspectives.

DRUG DISCOVERY & DEVELOPMENT

Finding and developing drugs is a lengthy process that involves searching, designing, and testing new drugs to fulfill fundamental health needs. Once a candidate molecule is identified, it is also tested in preclinical and clinical studies, where its safety, efficacy, and potential side effects are determined. Such procedures may take years and have to be done with cooperative efforts from scientists, doctors, regulatory agencies, and drug manufacturers. Despite all these problems, successful drug discovery will lead to novel therapies, thereby enhancing the condition of patients and improving medical science [4, 5].

In recent years, technological advancements have significantly transformed the majority of factors involved in the drug discovery process, facilitating and accelerating individual phases. High-throughput screening techniques enable scientists to rapidly evaluate thousands of chemicals for potential therapeutic benefits, thereby significantly accelerating the primary discovery phase [6].

Furthermore, computational strategies, including AI, are increasingly finding applications in predicting the properties and behaviors of drug candidates, thereby reducing the reliance on the traditional trial-and-error approach [7, 8]. ML is a significant area within AI, allowing machines to learn from data without being programmed [9]. ML algorithms have been very effectively applied in various niches of drug discovery, such as genomics, proteomics, and transcriptomics, having revealed important molecular pathways and molecular biomarkers related to the pathologies of many diseases. This has enabled the validation and prioritization of tractable drug targets. ML may one day eradicate, if not minimize, testing on live animals [10]. Fig. (1) shows the various applications of AI in drug discovery and development.

A study by Margulis [11] and his group is one such example of the use of ML in drug discovery. The aim was to explore how ML can be useful in identifying highly bitter compounds in the early stages of drug development. The aim was to understand if a specific ML algorithm can be used as an alternative to in vivo testing to predict the bitterness of different drug molecules. Eighty percent of the bitter compounds present were matched to those associated with a brief access taste aversion (BATA) test, indicating that the above research was successful. This experiment, following the BATA test, revealed that toxicity should not be directly linked to being bitter, as scientists had hypothesized over time. This denotes how ML can produce required outputs with new knowledge simultaneously. Fig. (2) represents machine learning in drug design.

The study by Raschka et al. [12, 13] shows the functionality and applicability of ML technology in GPCR ligand recognition, which is an important concern regarding drug design. The task is to determine if older-fashioned technology used for blocking Sea Lamprey Receptor 1 (SLOR1) receptor signal inhibiting tests can be replaced with newly attained results from the ML algorithm, as validated by the described use of these tests. The results generated by the algorithm were close to the benchmark set; therefore, the novel algorithm could replace the older one for identifying other drugs' features.

Two experiments, conducted by Rantanen and Khinast [14] and Turki and Taguchi [15], respectively, fall into other groups of ML and are therefore best compared. The paper published by Turki and Taguchi was a reinforcement learning exercise that utilized three necessary frameworks to sustain ML, along with its two sister approaches, supervised and unsupervised learning, aimed at accelerating the search for potentially useful drugs. Conversely, Zhavoronkov and Mamoshina applied transfer learning to predict the response of myeloma patients to an existing drug. Transfer learning is an ML problem that involves the application of...